Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the EGFR inhibitor, Cetuximab in patients with mCRC harboring APC, TP53 and RAS mutations.

本研究为一项纳入21例患者的前瞻性多中心II期临床试验，旨在评估表皮生长因子受体抑制剂（EGFR inhibitor）西妥昔单抗（Cetuximab）对携带APC、TP53及RAS基因突变的转移性结直肠癌（metastatic colorectal cancer, mCRC）患者的临床疗效。